Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17239111 | 0.84 | PTGS1 (0.39) | LMNABLMPTGS1PDE4ASLC6A6 | |
| SCHEMBL8608172 | 0.84 | TSHR (0.33) | — | |
| Ammonia Solution, Strong SCHEMBL9784969 | 0.82 | TSHR (0.32) | — | |
| SCHEMBL27832263 | 0.80 | CA1 (0.35) | LMNAALDH1A1ALOX15KDM4E | |
| SCHEMBL3732159 | 0.79 | KDM4E (0.36) | LMNAALDH1A1SMN1; SMN2MAPTALOX15 | |
| SCHEMBL29104746 | 0.79 | PTGS1 (0.39) | LMNABLMPTGS1PDE4ASLC6A6 | |
| SCHEMBL7098756 | 0.78 | LMNA (0.35) | LMNABLMSLC6A6CYP2C19ALDH1A1 | |
| SCHEMBL28363466 | 0.78 | CA1 (0.46) | BLMRECQL | |
| SCHEMBL28180126 | 0.78 | CA1 (0.36) | LMNABLMPTGS1PDE4ASLC6A6 | |
| SCHEMBL4457159 | 0.78 | PTGS1 (0.35) | LMNABLMPTGS1PDE4ASLC6A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300472-B1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2012-01-18 | — | — | EP | claimed |
| US-8058294-B2 | Of N-[2-(Diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propanamide; asthma and chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2011-11-15 | — | — | US | claimed |
| EP-2364704-A1 | Combination of beta-adrenoceptor agonist and corticosteroid | AstraZeneca AB (SE) | 2011-09-14 | — | — | EP | claimed |
| JP-2011524897-A | — | — | 2011-09-08 | — | — | JP | claimed |
| WO-2011073662-A1 | COMBINATION OF A BENZOXAZINONE AND A FURTHER AGENT FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | WO | claimed |
| EP-2303266-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A 4-HYDROXY-2-OXO-2, 3- DIHYDRO-1, 3-BENZOTHIAZOL-7-YL COMPOUND FOR MODULATION OF BETA2-ADRENORECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | claimed |
| EP-2300472-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2011-03-30 | — | — | EP | claimed |
| WO-2011012897-A1 | NEW COMBINATIONS FOR THE TREATMENT OF ASTHMA | ASTRAZENECA AB (SE) | 2011-02-03 | — | — | WO | claimed |
| US-20120101091-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-26 | — | — | US | disclosed |
| EP-1569919-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2012-04-18 | — | — | EP | disclosed |
| EP-2417140-A1 | INHIBITORS OF HIV REPLICATION | Boehringer Ingelheim International GmbH (DE) | 2012-02-15 | — | — | EP | disclosed |
| US-20120034187-A1 | Hepatitis C Inhibitor Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-09 | — | — | US | disclosed |
| EP-2414376-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A STEROIDAL[3,2-C]PYRAZOLE DERIVATIVE AND A SECOND PHARMACEUTICALLY ACTIVE COMPOUND | AstraZeneca AB (SE) | 2012-02-08 | — | — | EP | disclosed |
| US-20120028941-A1 | Pharmaceutical Product Comprising a P38 Kinase Inhibitor and a Second Active Ingredient | ASTRAZENECA UK LIMITED (GB) | 2012-02-02 | — | — | US | disclosed |
| WO-2005004763-A1 | DIFFUSION LAYER MODULATED SOLIDS | PHARMACIA & UPJOHN COMPANY LLC. (US) | 2005-01-20 | — | — | WO | disclosed |
| US-20050004053-A1 | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection | GANGULY ASHIT K (US) | 2005-01-06 | — | — | US | disclosed |
| EP-0854136-B1 | Process for the production of pure alkanesulfonic acids | ASAHI DENKA KOGYO KK (JP) | 2001-11-14 | — | — | EP | disclosed |
| US-6008303-A | Polymers suitable as dispersing resins | BASF AKTIENGESELLSCHAFT (DE) | 1999-12-28 | — | — | US | disclosed |
| US-5912385-A | Process for the production of pure alkanesulfonic acids | TOKAI DENKA KOGYO KABUSHIKI KAISHA (JP) | 1999-06-15 | — | — | US | disclosed |
| EP-0854136-A1 | Process for the production of pure alkanesulfonic acids | Tokai Denka Kogyo K.K. (JP) | 1998-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004053-A1 | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection | IFNAR1, EIF2AK2, IFNG | LMNA 2374/4885BLM 1738/4885PTGS1 2250/4885 |
| US-20120034187-A1 | Hepatitis C Inhibitor Compounds | HAVCR2, CTRL, CTRC | LMNA 816/4885BLM 2110/4885PTGS1 1238/4885 |
| US-20120028941-A1 | Pharmaceutical Product Comprising a P38 Kinase Inhibitor and a Second Active Ingredient | NR3C2, ARRB1, GRK4 | LMNA 3255/4885BLM 2877/4885PTGS1 18/4885 |
| US-20120101091-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2E | LMNA 1290/4885BLM 2261/4885PTGS1 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.